If you’re researching treatments for PTSD or treatment-resistant anxiety, you’ve probably come across both TMS and Stellate Ganglion Block (SGB). They get mentioned in the same sentences a lot, but they’re radically different procedures with different mechanisms, timelines, and best-fit patients.
What You’ll Learn
- How TMS and SGB actually work — and why one is electromagnetic and the other is anesthetic
- Where the evidence is strongest for each
- Cost, insurance, and access realities in 2026
- When clinicians actually choose one over the other (and when they use both)
The Mechanism Gap
These treatments operate on completely different parts of the system.
TMS uses focused magnetic pulses through a coil placed against the scalp to stimulate neurons in specific brain regions. For PTSD and depression, the most common target is the dorsolateral prefrontal cortex (DLPFC) — the area that helps regulate emotional reactivity. The goal is to strengthen prefrontal control and rebalance the prefrontal-amygdala circuit over a course of 20-30 sessions.
SGB is an anesthetic injection. A local anesthetic (typically bupivacaine or ropivacaine) is delivered to the stellate ganglion — a cluster of sympathetic nervous system nerves at the base of the neck (C6-C7 area). The block temporarily quiets sympathetic outflow on that side of the body and head. The hypothesis for PTSD: hyperactive sympathetic nervous system signaling drives much of the hyperarousal, hypervigilance, and intrusion symptoms. Quiet the system at this gateway and you can reset the chronic threat response.
Same target outcome (less PTSD), wildly different paths.
Speed of Onset
This is where the gap is biggest.
SGB: Many patients describe feeling different within hours. Hyperarousal dropping. Sleep improving the first night. Hypervigilance softening. The full effect typically settles in over 1-3 days.
TMS: Effects emerge gradually over 2-6 weeks. Sleep improvements often come first (week 2), then energy, then mood and anxiety reductions (weeks 3-4), with continued consolidation through week 6.
For a patient in acute crisis or someone who needs to function for a major life event in the next two weeks, the SGB timeline is the right shape. For ongoing treatment of chronic PTSD or comorbid depression, the TMS timeline is acceptable.
Durability
SGB: Effects from a single block often last 3-6 months in responders. Some patients get longer durability after a series of 2-3 blocks at 1-2 week intervals.
TMS: A standard course produces effects that last 6-12 months for most responders, with maintenance options available indefinitely. Re-treatment courses for prior responders are typically successful.
Both treatments often need ongoing maintenance. Neither is a one-and-done cure.
Evidence Base
TMS for PTSD:
- Multiple randomized controlled trials, including in veterans
- The VA has done significant program-level work, with several VA medical centers offering TMS as part of PTSD care
- Effect sizes consistently moderate; response rates 40-60% for treatment-resistant cases
- Comorbid depression typically improves alongside
SGB for PTSD:
- Several randomized controlled trials, with mixed but mostly favorable results
- A 2020 RCT in veterans with PTSD showed clinically meaningful improvements in PTSD symptoms with active SGB versus sham
- A 2024 Department of Defense-funded study added to the supportive evidence base
- Best-studied in veterans and active-duty service members; growing civilian use
The honest summary: both have meaningful evidence in PTSD but are off-label uses of treatments primarily approved for other indications (TMS for depression; SGB for chronic pain). Neither is FDA-approved specifically for PTSD as of 2026.
Cost and Access
TMS:
- Insurance-covered for depression diagnoses with the standard prior-auth pathway. ~$300-$1,000 per course in copays for most insured patients. Self-pay full course $9,000-$15,000.
- Off-label PTSD use is sometimes covered when comorbid depression provides the qualifying diagnosis.
- Available at thousands of clinics nationwide.
SGB:
- Generally not covered by insurance for PTSD. Covered when used for chronic regional pain syndromes.
- $1,500-$4,000 per single-side injection cash-pay; bilateral or repeat blocks add cost.
- Available at fewer clinics — mostly anesthesiology, pain medicine, and a growing number of trauma-specialty programs.
- Veterans can often access SGB through the VA, which has been increasingly offering it under research and pilot programs.
Side Effects and Risk Profile
TMS:
- Most common: scalp discomfort during pulses (4-6/10 in week 1, mostly resolving), headaches in 20-30% of patients in the first week, occasional facial muscle twitches.
- Serious: seizure risk roughly 1 in 30,000 sessions — extremely rare but the most significant risk.
- No post-procedure restrictions; patients drive themselves home and return to work immediately.
SGB:
- Common: temporary Horner’s syndrome on the injected side (drooping eyelid, small pupil, facial flushing) — expected and resolves in 4-12 hours. Mild hoarseness or temporary swallowing changes possible.
- Serious: rare but real risks of bleeding, vascular puncture, or pneumothorax. Done under ultrasound guidance to minimize.
- Same-day post-procedure restrictions: someone drives you home, no major activity for 24 hours.
Both are safe in experienced hands; SGB carries higher procedural risk because it’s an actual injection, while TMS is fully non-invasive.
When Clinicians Actually Choose One Over the Other
TMS first is typically the right call when:
- The patient has comorbid depression (TMS treats both)
- Insurance coverage is needed
- Cost is a major constraint
- Medications haven’t worked but the situation isn’t crisis-level
SGB first is typically the right call when:
- Symptoms are severe and the patient needs rapid relief
- The patient has prominent autonomic/hyperarousal symptoms (heart racing, hypervigilance, startle response)
- The patient needs to function within days for an important reason (court date, work, family event)
- TMS has been tried and didn’t work for the autonomic symptoms specifically
- A short bridge is needed while waiting to start trauma-focused therapy
Both used together is increasingly common in trauma specialty programs:
- SGB first to produce rapid symptom relief
- That relief makes the patient more capable of engaging in trauma-focused therapy (CPT, PE, EMDR)
- TMS course in parallel or after, for longer-term consolidation
- Maintenance with whichever produced better individual response
Bottom Line
These treatments aren’t really competing. They’re tools for different windows in the same overall recovery.
For most insured patients with chronic PTSD and depression, TMS is usually the more accessible starting point — covered by insurance, longer-lasting effects, broader availability.
For patients in acute crisis, with prominent autonomic hyperarousal, or needing fast relief for a specific reason, SGB is the more time-appropriate option — even though it requires self-pay.
For patients who can pursue both, a sequenced approach is increasingly considered best practice in trauma specialty care: SGB for rapid relief, trauma-focused therapy as the foundation, TMS for longer-term remodeling, and maintenance of whichever response holds best.
The right starting point is a trauma-trained psychiatrist who knows both treatments — not a clinic that only offers one and recommends it for everything.